Table 27.
Risperidone for children and adolescents with anorexia nervosa
| Certainty assessment | Impact | Certainty | Importance | ||||||
|---|---|---|---|---|---|---|---|---|---|
| № of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | |||
| Weight (assessed with: kg), Psychological Symtpoms, Side Effects | |||||||||
| 1 | randomised trials | not serious | not serious | not serious | not serious | none | There were no significant differences in weight at end of study (risperidone n = 18, placebo n = 22). Even when just data from those under age 18 (placebo 18, risperidone 12) were analyzed separately, there were no differences. Mean dose 2.5 mg over 9 weeks. |
⨁⨁⨁⨁ HIGH |
CRITICAL |
| not serious | not serious | not serious | not serious | none | There were no significant differences at end of study on any subscale of the EDI (Eating Disorders Inventory). |
⨁⨁⨁⨁ HIGH |
CRITICAL | ||
| not serious | not serious | not serious | not serious | none | ECG, bloodwork (prolactin, lipids, liver enzymes, glucose) no differences. Patient in the treated group reported fatigue and dizziness. |
⨁⨁⨁⨁ HIGH |
CRITICAL | ||
| Weight (assessed with: kg), Psychological Symptoms | |||||||||
| 4 | Case Reports | very serious a | not serious | not serious | serious a | none | Weight generally increased pre to post study period by several kg in 4 cases. |
⨁◯◯◯ VERY LOW |
CRITICAL |
| very serious a | not serious | not serious | serious a | none | Psychological symptoms including willingness to eat improved over the study period. Rigidity decreased. (n = 4) |
⨁◯◯◯ VERY LOW |
CRITICAL | ||